FDA Approves Perjeta First Neoadjuvant Drug for Breast Cancer

FDA Approves Perjeta First Neoadjuvant Drug for Breast Cancer

Great news for all the breast cancer heroines: the U.S. Food and Drug Administration (FDA) has approved the first neodjuvant drug for treatment of early-stage breast cancer. Rocher’s Perjeta (pertuzumab) was selected as part of a complete therapy regimen to treat early-stage, metastatic HER2-positive breast cancer. HER2 is a certain protein that is present in only 20% […]

1 22 23 24